Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Return on Sales (2019 - 2025)

BridgeBio Pharma's Return on Sales history spans 7 years, with the latest figure at 1.26% for Q4 2025.

  • For Q4 2025, Return on Sales rose 4022.0% year-over-year to 1.26%; the TTM value through Dec 2025 reached 1.33%, up 94.0%, while the annual FY2025 figure was 1.46%, 99.0% up from the prior year.
  • Return on Sales for Q4 2025 was 1.26% at BridgeBio Pharma, down from 1.24% in the prior quarter.
  • Across five years, Return on Sales topped out at 217.55% in Q4 2021 and bottomed at 433.5% in Q3 2022.
  • The 5-year median for Return on Sales is 42.03% (2023), against an average of 67.2%.
  • The largest YoY upside for Return on Sales was 134872bps in 2021 against a maximum downside of -40886bps in 2021.
  • A 5-year view of Return on Sales shows it stood at 217.55% in 2021, then plummeted by -136bps to 77.61% in 2022, then tumbled by -42bps to 110.09% in 2023, then soared by 62bps to 41.49% in 2024, then soared by 97bps to 1.26% in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Return on Sales are 1.26% (Q4 2025), 1.24% (Q3 2025), and 1.64% (Q2 2025).